Literature DB >> 2851650

Inhibitory influences of envelope glycoproteins of HIV-1 on normal immune responses.

N Chirmule1, V Kalyanaraman, N Oyaizu, S Pahwa.   

Abstract

Infection with the human immunodeficiency virus (HIV-1) leads to a wide range of immunological abnormalities. We have shown that native envelope glycoproteins (gp120) of HIV-1 inhibit antigen-specific and anti-CD3 induced lymphoproliferation of normal lymphocytes. We have demonstrated that gp120 binds to CD4 positive T lymphocytes and is internalized. These studies suggest that interaction of gp120 with the CD4 receptor may be sufficient to inhibit antigen-specific T cell responses that are mediated via the CD3-Ti receptor complex. Such an event could represent another mechanism by which the overall immune function of the CD4 positive T lymphocyte is depressed and may be relevant in planning investigations on the ongoing vaccine trial involving envelope glycoproteins.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2851650

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  8 in total

1.  Requirement of the T cell receptor for antigen presentation by T lymphocytes. Effect of envelope glycoproteins of HIV-1 on antigen presentation by T cells.

Authors:  N Chirmule; V S Kalyanaraman; H Slade; N Oyaizu; S Pahwa
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

2.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.

Authors:  J P Moore; J A McKeating; Y X Huang; A Ashkenazi; D D Ho
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 envelope glycoprotein gp120 produces immune defects in CD4+ T lymphocytes by inhibiting interleukin 2 mRNA.

Authors:  N Oyaizu; N Chirmule; V S Kalyanaraman; W W Hall; R Pahwa; M Shuster; S Pahwa
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

Review 4.  Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions.

Authors:  N Chirmule; S Pahwa
Journal:  Microbiol Rev       Date:  1996-06

5.  Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant.

Authors:  J C Griffiths; E L Berrie; L N Holdsworth; J P Moore; S J Harris; J M Senior; S M Kingsman; A J Kingsman; S E Adams
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

6.  Human immunodeficiency virus-1 glycoproteins gp120 and gp160 specifically inhibit the CD3/T cell-antigen receptor phosphoinositide transduction pathway.

Authors:  D Cefai; P Debre; M Kaczorek; T Idziorek; B Autran; G Bismuth
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

7.  Enzyme-linked immunoassay for human immunodeficiency virus type 1 envelope glycoprotein 120.

Authors:  M Gilbert; J Kirihara; J Mills
Journal:  J Clin Microbiol       Date:  1991-01       Impact factor: 5.948

8.  Expression of the extracellular domain of the human immunodeficiency virus type 1 envelope protein and its fusion with beta-galactosidase in Saccharomyces cerevisiae.

Authors:  W F Liu; D Gao; Z N Wang
Journal:  Clin Diagn Lab Immunol       Date:  1998-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.